AbbVie Header AbbVie Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"AriBio","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$770.0 million","upfrontCash":"$90.0 million","newsHeadline":"AriBio Licenses Exclusive Marketing Rights for AR1001 for Alzheimer\u2019s Disease in China for $770 Million USD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for Mirodenafil

    Menu

    Mirodenafil

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              AriBio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AriBio Licenses Exclusive Marketing Rights for AR1001 for Alzheimer’s Disease in China for $770 Million USD

              Details:

              AriBio has concluded an exclusive distribution agreement with a Chinese pharmaceutical company for AR1001 (mirodenafil), an oral PDE5 inhibitor, for the treatment for Alzheimer's disease, in China.

              Lead Product(s): Mirodenafil

              Therapeutic Area: Neurology Product Name: AR1001

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $770.0 million Upfront Cash: $90.0 million

              Deal Type: Agreement March 24, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
              Skyepharma, an Expert and Innovative CDMO Partner for tailor-made solutions in complex oral solids and bioproduction.
              Post Enquiry
              POST ENQUIRY